Dr. Sarah Anne Kremen, MD

Dr. Kremen practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Kremen's NPI, 1144348848, was assigned on March 27, 2007. Dr. Kremen graduated from University of Maryland School of Medicine - Baltimore in 2003. Dr. Kremen holds California license A89326.

Dr. Kremen's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Kremen's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. The medical group on file is Cedars-Sinai Medical Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kremen practices. Vendor and product names are available with a free account.

Neurology is Dr. Kremen's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Kremen is board certified in neurology by the American Board of Psychiatry and Neurology. Dr. Kremen is licensed in California.

Dmand AI lists alzheimer's disease, encephalopathy, hereditary polyneuropathy, lower back pain, migraine and chronic headache and non-alzheimer's dementia (chronic) among the conditions Dr. Kremen treats.

CMS data shows 269 Medicare services from Dr. Kremen across 5 procedure codes in 2024, for 163 Medicare patients. Medicare paid $22,011 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 163 Medicare patients who saw Dr. Kremen in 2024. The largest group is 75 to 84, with 82 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 25% are also on Medicaid. Their average risk score is 1.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kremen's median patient age at 76, with 55% women.

In 2024, Dr. Kremen wrote 153 Medicare Part D claims for 44 patients. 95% of them were for generic drugs. CMS names the drug for 126 of them, across 5 drugs with 11 or more claims each, at $4,690 in total drug cost. In 2023, CMS named 134 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Kremen for performance year 2024, reported as part of a group. Dr. Kremen accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kremen as offering telehealth.

Dmand AI links 8 papers to Dr. Kremen, published from 2010 to 2022. 2016 was the busiest year, with 3. Dr. Kremen has published most often in Alzheimers Dement. Dr. Kremen's most frequent co-authors are Edmond Huatung Teng, MD, PhD, Po-Heng Tsai, MD and Paul Stephen Aisen.

Dmand AI links Dr. Kremen to 13 clinical trials, 6 of them phase 3 studies. 3 are still active or recruiting. Conditions studied include Alzheimer Disease, Tauopathies and Cognition Disorders. Eli Lilly and Company sponsors the most, 3. Open Payments lists research payments to Dr. Kremen that name 2 trials.

CMS Open Payments shows 29 general payments to Dr. Kremen from 6 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 57% of the total. Eli Lilly and Company paid the most, $3,825. It also lists 3 research payments totaling $2,571 from 2020 to 2022, naming 2 clinical trials.

Dr. Kremen graduated from University of Maryland School of Medicine - Baltimore in 2003. Dr. Kremen is a member of AAN.

Dr. Kremen is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.